India rejects Abbott's patent application for Kaletra
This article was originally published in Scrip
Executive Summary
India has rejected Abbott's patent application for its antiretroviral drug, Kaletra/Aluvia (lopinavir plus ritonavir), following opposition from the US-based non-profit group, Initiative for Medicines, Access and Knowledge (I-MAK), as well as Cipla, Matrix Laboratories (now part of Mylan) and the private Indian firm, Okasa.